Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nature's Way/Efamol introduce Efalex Focus for EFA-"deficient" children.

This article was originally published in The Tan Sheet

Executive Summary

NATURE's WAY/EFAMOL EFALEX FOCUS FOR EFA-"DEFICIENT" CHILDREN provides "essential fatty acids found to be deficient in many children struggling with coordination, visual difficulties, learning ability and behaving at school," a product brochure states. "Best of all," Efalex Focus is a "safe and natural alternative. And that's especially important to parents concerned about what they give their children," the companies claim. The brochure portrays a child hunched over a book, with the tagline "Help him to see reason. Naturally."

You may also be interested in...



Efamol Nutraceuticals

National Advertising Division of the Council of Better Business Bureaus terminates its inquiry into advertising for Efamol's Efalex dietary supplement because the claims already are undergoing regulatory review. NAD had requested Efamol provide substantiation for claims made in a print ad that use of Efalex is an efficient way to manage fatty acid deficiency in children and implied claims the product can be used to treat Attention Deficit-Hyperactivity Disorder. Distributed by Nature's Way, Efalex for essential fatty acid-"deficient" children began shipping in July 1997 (1"The Tan Sheet" July 28, 1997, p. 17). Royal Numico acquired Efamol in 1998 (2"The Tan Sheet" July 12, p. 3)

Efamol Nutraceuticals

National Advertising Division of the Council of Better Business Bureaus terminates its inquiry into advertising for Efamol's Efalex dietary supplement because the claims already are undergoing regulatory review. NAD had requested Efamol provide substantiation for claims made in a print ad that use of Efalex is an efficient way to manage fatty acid deficiency in children and implied claims the product can be used to treat Attention Deficit-Hyperactivity Disorder. Distributed by Nature's Way, Efalex for essential fatty acid-"deficient" children began shipping in July 1997 (1"The Tan Sheet" July 28, 1997, p. 17). Royal Numico acquired Efamol in 1998 (2"The Tan Sheet" July 12, p. 3)

Efamol Nutraceuticals

National Advertising Division of the Council of Better Business Bureaus terminates its inquiry into advertising for Efamol's Efalex dietary supplement because the claims already are undergoing regulatory review. NAD had requested Efamol provide substantiation for claims made in a print ad that use of Efalex is an efficient way to manage fatty acid deficiency in children and implied claims the product can be used to treat Attention Deficit-Hyperactivity Disorder. Distributed by Nature's Way, Efalex for essential fatty acid-"deficient" children began shipping in July 1997 (1"The Tan Sheet" July 28, 1997, p. 17). Royal Numico acquired Efamol in 1998 (2"The Tan Sheet" July 12, p. 3)

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel